A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
There are 2 parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of BLU-285 when given to patients with advanced systemic mastocytosis (AdvSM) or relapsed (has come back) or refractory (has not responded to treatment) myeloid malignancies. The goal of Part 2 of this study is to learn if the dose of BLU-285 found in Part 1 is safe and well-tolerated in patients with AdvSM or relapsed or refractory myeloid malignancies. This is one of the first trials using BLU-285 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: BLU-285
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Blueprint Medicines Corp.
IRB Review and Approval Date: 03/31/2016
Recruitment Status: Open
Projected Accrual: 60
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: